Search

everythinglearnresearchcommunity

for

Search:↓

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.

New medications could improve treatment for severe alopecia areata in Australia.

Cyclosporine improved skin condition in dogs with sebaceous adenitis.

Dupilumab helped a 4-year-old grow hair back after another treatment failed.

Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.

Certain proteins are significantly increased in the skin of people with hidradenitis suppurativa.

A new mix of anthralin and calcipotriene might help treat severe hair loss.

Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

CGF therapy may effectively treat psoriasis by reducing inflammation.

3D imaging effectively tracks skin changes in vitiligo treatment.

Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

Retinoids and narrowband UVB phototherapy are effective for treating psoriasis and can reduce treatment time when used together.

PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.

The document concludes that various topical treatments show promise for skin conditions like atopic dermatitis, psoriasis, and hair loss.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

Upadacitinib effectively treats severe alopecia areata and is safe.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Topical ruxolitinib quickly improves non-segmental vitiligo.

New subcision technique with a bent needle and syringe improves ease, effectiveness, and comfort for treating acne scars.

Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.